AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02457143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call
Study NCT01481818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGCG
Description: Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
Study NCT00264732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amolimogene
Description: 1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.
Study NCT00264732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amolimogene
Description: 3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.
Study NCT00264732 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.
Study NCT02535806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: 4 doses of study drug will be given.
Study NCT02535806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intrathecal dose For CNS negative patients, Day 1 and Day 8
Study NCT02535806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate / Hydrocortisone / Cytarabine
Description: Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
Study NCT02535806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Days 1-5 and 15-19
Study NCT02535806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Days 1 and 2
Study NCT02535806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Days 1, 8, 15, 22
Study NCT02535806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Days 3 and 17
Study NCT01483521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical home visitation
Description: Clinical Home visitation consisted of once a month visits to families on the experimental group. During those visits home visitors facilitated developmentally appropriate play guidance and co-construction tasks for the dyad.
Study NCT03616028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left atrial appendage closure
Description: Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the CLAAS device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
Study NCT01123902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand-held fan
Description: Patients are instructed to direct the hand-held fan towards the face around the central part of the face, the sides of the nose and above the upper lip. The hand-held fan has three soft rotor blades and an unfoldable rotor unit.
Study NCT01123902 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wristband
Description: Patients are instructed to wear the wristband continually and pull it regularly at short intervals when breathless or during breathlessness attacks.
Study NCT02357771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic (L. brevis CD2 lozenges)
Description: Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
Study NCT02357771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Study NCT00638014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Sternal Closure System
Description: Sternal talons will be used and supplemented with wires
Study NCT00638014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional wire closure
Description: Conventional wire closure of sternum
Study NCT02109497 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PBT2
Description: PBT2 250 mg administered
Study NCT02196662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBD98-M:
Description: single adiministration
Study NCT02196662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBD98-M without HA
Description: single adiministration
Study NCT02196662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delzicol
Description: single adiministration
Study NCT05740501 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05740501 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study NCT05740501 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03522896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: balancing sugars and organic acids
Study NCT03522896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test meal 1
Description: orange juice plus hesperidin low dose
Study NCT03522896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test meal 2
Description: orange juice plus hesperidin higher dose
Study NCT03522896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test meal 3
Description: diluted orange juice plus hesperidin low dose
Study NCT04798404 — intervention group
Intervention type: OTHER
Intervention: Multimodal exercise intervention
Description: The intervention conducted was a progressive multicomponent training protocol. The training consisted on 2 collective sessions of 1h per week, during 10 weeks. Sessions involved functional exercises, muscular reinforcement performed at body-weight or with small materials (elastic bands or dumbbells), balance, and adapted sport and physical activities. Progression was based on an increase in workload (or in muscle strains). The workload was considered as the interaction of intensity and volume of exercise (set x repetitions). Intensity was based on effort tolerance, modulate by contraction regimen, velocity and load (elastic bands stiffness). Participants were encouraged to reproduce exercises at home when they were performed easily in supervised collective sessions.
Study NCT04434456 — intervention group
Intervention type: DEVICE
Intervention: CGuard stent implantation
Description: CGuard stent implantation in the carotid artery with symptomatic, dissecting or enlarging aneurysm
Study NCT01926561 — intervention group
Intervention type: OTHER
Intervention: Interscalene brachial plexus block
Description: After sterile draping around interscalene groove with povidone, a nerve stimulating needle connected to a nerve stimulator is inserted through the interscalene groove. Following involuntary contraction of shoulder, arm, forearm, or hand muscles with 0.5 milliamperes at 1 Hz using the nerve stimulator, 30 to 40 ml of mixture of 1% mepivacaine 20 ml and 0.75% ropivacaine 20 ml are injected.
Study NCT00110448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81 mg or 100 mg per day
Study NCT00110448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No aspirin
Description: No aspirin use
Study NCT01529567 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy without exposure
Description: 10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, and guided behavioral change aiming to increase quality of life and flexibility.
Study NCT01529567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with exposure
Description: 10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, guided behavioral change aiming to increase quality of life and flexibility, and systematic exposure to IBS symptoms and aversive situations.
Study NCT02708186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelotanserin
Description: once daily, oral, 20-mg tablets
Study NCT02708186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral, matching tablets
Study NCT01020240 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Avolition
Description: - avolition for cesarean discomforts
Study NCT01020240 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Orientation
Description: * avolition of cesarean discomfort~* physiotherapy orientation
Study NCT01020240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guide
Description: * avolition of cesarean discomfort~* physiotherapy orientation~* guide orientation
Study NCT01072643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: This is a single center, dose escalation study of Dexmedetomidine in pediatric subjects with pulmonary hypertension (PVR>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine.
Study NCT02817464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46046 - 400 mg/mL
Description: A single subcutaneous injection in the abdomen of undiluted TV-46046 - 400 mg/mL
Study NCT02817464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46046 - 200 mg/mL
Description: A single subcutaneous injection in the abdomen of saline-diluted TV-46046 - 200 mg/mL
Study NCT00540085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 0.6 mg/kg given intravenously before intubation
Study NCT05914337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested.
Study NCT05914337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gene expressions of miRNA
Description: In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
Study NCT01696188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interscalene nerve catheter
Study NCT03229785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Blood Plasma
Description: Plasma collected from human umbilical cord blood
Study NCT02460419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02460419 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best supportive care (BSC)
Description: Best supportive care and following-up every 6-8 weeks
Study NCT02460419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care (BSC)
Description: Best supportive care and following-up every 6-8 weeks
Study NCT03214848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive education prior to abortion
Description: Contraceptive education script will be delivered over the phone prior to abortion visit.
Study NCT00888940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecallantide
Description: 2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
Study NCT00888940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyklokapron(R)
Description: 1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
Study NCT02751489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bain De Soliel - Solid
Description: 0.05 gm/cm2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.
Study NCT06330558 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic right adrenalectomy
Description: adrenalectomy
Study NCT05102032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mini invasive approach
Description: using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
Study NCT05102032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional approach
Description: laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
Study NCT04422483 — intervention group
Intervention type: OTHER
Intervention: Realist evaluation
Description: In-depth exploration of individual service models will be carried out to determine the interrelationship of context, intervention, mechanisms and outcomes as they occur in their natural setting. Data will be gathered within case studies using mixed methods at two levels: (i) service model and (ii) individual child/ family. Methods will include semi structured realist Interviews, focus groups, and document reviews to assemble a comprehensive description of the service and model. Interviewees will include commissioners, service managers, clinicians, referrers, parents and young people. Interviews will be recorded and transcribed, proceeding to qualitative analysis based on components of the programme theory. Regular team meetings will discuss coding, address inconsistencies, and refine collective understanding of coding framework. Coded data will be collated using NVivo software.
Study NCT02790190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose
Study NCT01106248 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eribulin Mesylate
Description: 1.4 mg/m\^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
Study NCT01694797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Study NCT01694797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate
Study NCT04433416 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hypertension
Description: If the patient has two or more blood pressure values ≥140/90mmHg in a calm state, he is included in this group
Study NCT03651297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training with Fall-Arrest harness
Description: This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a standard Fall-Arrest harness for safety throughout, but no other external support. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
Study NCT03651297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training with Adjustable harness
Description: This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a motorized harness in which the support provided is adjustable. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
Study NCT02141204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRV Liquid
Description: Two doses administered orally according to a 0, 1-month schedule.
Study NCT02141204 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HRV Lyophilized
Description: Two doses administered orally according to a 0, 1-month schedule.
Study NCT01497561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
Study NCT01497561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
Study NCT02454842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-4000 (Tarloxotinib)
Description: TH-4000 (Tarloxotinib) is a hypoxia-activated prodrug
Study NCT02653599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP273
Study NCT02653599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02653599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03313037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine
Study NCT03313037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: Pneumococcal conjugate vaccine
Study NCT03313037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal polysaccharide vaccine
Study NCT03313037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo
Study NCT01918306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.~In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~--------------------------------------------------------------------------------
Study NCT01918306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.~In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~--------------------------------------------------------------------------------
Study NCT01918306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative studies
Study NCT01918306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: correlative studies
Study NCT01918306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative studies
Study NCT01918306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: correlative studies
Study NCT01918306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI
Description: correlative studies
Study NCT01918306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI
Description: correlative studies
Study NCT01918306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC -0941
Description: Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
Study NCT02441595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCP
Description: Eight weekly sessions 2,5 h and homework 30 min/day. Practicing various mindfulness meditations coupled with practical skills and theory of birthing and parenting.
Study NCT02441595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoprophylaxis
Description: Three sessions 3h each, and practices to do at home. Practical skills of relaxation and breathing techniques for labor as well as knowledge of birthing and parenting.
Study NCT03458819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of peritoneal mesothelial cells
Description: HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.
Study NCT01516021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intake of high or low fat yoghurt
Description: intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day